{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:55:44Z","timestamp":1785488144563,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ferring Pharmaceuticals"},{"name":"CONARIS Research Institute AG"},{"name":"German Excellence Cluster \u201cInflammation at Interfaces\u201d","award":["ExC306"],"award-info":[{"award-number":["ExC306"]}]},{"name":"SysINFLAME consortium of the German Ministry of Education and Research","award":["01ZX1306"],"award-info":[{"award-number":["01ZX1306"]}]},{"name":"Collaborative research center CRC1182 of the German Research Foundation","award":["C2"],"award-info":[{"award-number":["C2"]}]},{"name":"SYSCID consortium of the EU Horizon 2020 program","award":["733100"],"award-info":[{"award-number":["733100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00384-018-3069-8","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:30:28Z","timestamp":1525998628000},"page":"927-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases"],"prefix":"10.1007","volume":"33","author":[{"given":"Susanna","family":"Nikolaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg H.","family":"Waetzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Butzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ziolkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Al-Massad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"L\u00f6vgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte B.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten M.","family":"Reinheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Seegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rosenstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"3069_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.smim.2013.11.002","volume":"26","author":"J Scheller","year":"2014","unstructured":"Scheller J, Garbers C, Rose-John S (2014) Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26:2\u201312","journal-title":"Semin Immunol"},{"key":"3069_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.smim.2013.12.003","volume":"26","author":"MJ Waldner","year":"2014","unstructured":"Waldner MJ, Neurath MF (2014) Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 26:75\u201379","journal-title":"Semin Immunol"},{"key":"3069_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448\u2013457","journal-title":"Nat Immunol"},{"key":"3069_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","volume":"26","author":"F Schaper","year":"2015","unstructured":"Schaper F, Rose-John S (2015) Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 26:475\u2013487","journal-title":"Cytokine Growth Factor Rev"},{"key":"3069_CR5","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/0024-3205(90)90149-L","volume":"47","author":"Y Suzuki","year":"1990","unstructured":"Suzuki Y, Saito H, Kasanuki J, Kishimoto T, Tamura Y, Yoshida S (1990) Significant increase of interleukin 6 production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 47:2193\u20132197","journal-title":"Life Sci"},{"key":"3069_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000163637","volume":"59","author":"T Andus","year":"1991","unstructured":"Andus T, Gross V, Casar I, Krumm D, Hosp J, David M, Scholmerich J (1991) Activation of monocytes during inflammatory bowel disease. Pathobiology 59:166\u2013170","journal-title":"Pathobiology"},{"key":"3069_CR7","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/gut.32.12.1531","volume":"32","author":"YR Mahida","year":"1991","unstructured":"Mahida YR, Kurlac L, Gallagher A, Hawkey CJ (1991) High circulating concentrations of interleukin-6 in active Crohn\u2019s disease but not ulcerative colitis. Gut 32:1531\u20131534","journal-title":"Gut"},{"key":"3069_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/0016-5085(93)90336-B","volume":"104","author":"JS Hyams","year":"1993","unstructured":"Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL (1993) Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 104:1285\u20131292","journal-title":"Gastroenterology"},{"key":"3069_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/gut.36.1.45","volume":"36","author":"K Mitsuyama","year":"1995","unstructured":"Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K (1995) Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36:45\u201349","journal-title":"Gut"},{"key":"3069_CR10","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1111\/j.1572-0241.1999.01288.x","volume":"94","author":"W Reinisch","year":"1999","unstructured":"Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A, Lochs H (1999) Clinical relevance of serum interleukin-6 in Crohn\u2019s disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94:2156\u20132164","journal-title":"Am J Gastroenterol"},{"key":"3069_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/gut.2004.043554","volume":"54","author":"T Gustot","year":"2005","unstructured":"Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J, Franchimont D (2005) Profile of soluble cytokine receptors in Crohn\u2019s disease. Gut 54:488\u2013495","journal-title":"Gut"},{"key":"3069_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2249.2005.02960.x","volume":"143","author":"K Mitsuyama","year":"2006","unstructured":"Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A, Sata M (2006) A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143:125\u2013131","journal-title":"Clin Exp Immunol"},{"key":"3069_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s10620-007-9849-6","volume":"53","author":"S Nancey","year":"2008","unstructured":"Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B (2008) Serum interleukin-6, soluble interleukin-6 receptor and Crohn\u2019s disease activity. Dig Dis Sci 53:242\u2013247","journal-title":"Dig Dis Sci"},{"key":"3069_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","volume":"34","author":"C Garbers","year":"2015","unstructured":"Garbers C, Aparicio-Siegmund S, Rose-John S (2015) The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 34:75\u201382","journal-title":"Curr Opin Immunol"},{"key":"3069_CR15","doi-asserted-by":"publisher","first-page":"42959","DOI":"10.1074\/jbc.M111.295758","volume":"286","author":"C Garbers","year":"2011","unstructured":"Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Grotzinger J, Jones SA, Rose-John S, Scheller J (2011) Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 286:42959\u201342970","journal-title":"J Biol Chem"},{"key":"3069_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","volume":"94","author":"HC Reinecker","year":"1993","unstructured":"Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn\u2019s disease. Clin Exp Immunol 94:174\u2013181","journal-title":"Clin Exp Immunol"},{"key":"3069_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","volume":"6","author":"R Atreya","year":"2000","unstructured":"Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6:583\u2013588","journal-title":"Nat Med"},{"key":"3069_CR18","doi-asserted-by":"publisher","first-page":"16777","DOI":"10.1074\/jbc.M207999200","volume":"278","author":"P Lovato","year":"2003","unstructured":"Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Odum N (2003) Constitutive STAT3 activation in intestinal T cells from patients with Crohn\u2019s disease. J Biol Chem 278:16777\u201316781","journal-title":"J Biol Chem"},{"key":"3069_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1572-0241.2005.40615.x","volume":"100","author":"J Mudter","year":"2005","unstructured":"Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, Lehr HA, Schmidt J, Neurath MF (2005) Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 100:64\u201372","journal-title":"Am J Gastroenterol"},{"key":"3069_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/00054725-200502000-00001","volume":"11","author":"A Musso","year":"2005","unstructured":"Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, Sturm A, Fiocchi C, Rizzetto M, Pegoraro L, Sategna-Guidetti C, Brizzi MF (2005) Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 11:91\u201398","journal-title":"Inflamm Bowel Dis"},{"key":"3069_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/gut.2009.184176","volume":"59","author":"Y Li","year":"2010","unstructured":"Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ (2010) Disease-related expression of the IL6\/STAT3\/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59:227\u2013235","journal-title":"Gut"},{"key":"3069_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cc.9.4.10615","volume":"9","author":"C Neufert","year":"2010","unstructured":"Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A, Ouyang W, Neurath MF, Becker C (2010) Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 9:652\u2013655","journal-title":"Cell Cycle"},{"key":"3069_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/eji.201142327","volume":"42","author":"D Bernardo","year":"2012","unstructured":"Bernardo D, Vallejo-Diez S, Mann ER, Al-Hassi HO, Martinez-Abad B, Montalvillo E, Tee CT, Murugananthan AU, Nunez H, Peake ST, Hart AL, Fernandez-Salazar L, Garrote JA, Arranz E, Knight SC (2012) IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol 42:1337\u20131353","journal-title":"Eur J Immunol"},{"key":"3069_CR24","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1002\/j.1460-2075.1989.tb08554.x","volume":"8","author":"U Ganter","year":"1989","unstructured":"Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773\u20133779","journal-title":"EMBO J"},{"key":"3069_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.crohns.2012.12.012","volume":"7","author":"E Wine","year":"2013","unstructured":"Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, Crandall WV, Leleiko N, Muise AM, Griffiths AM, Turner D (2013) Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis 7:916\u2013922","journal-title":"J Crohns Colitis"},{"key":"3069_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","volume":"126","author":"H Ito","year":"2004","unstructured":"Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease. Gastroenterology 126:989\u2013996","journal-title":"Gastroenterology"},{"issue":"suppl. 1","key":"3069_CR27","first-page":"S12","volume":"10","author":"S Danese","year":"2016","unstructured":"Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S (2016) OP015 results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn\u2019s disease who are anti-tumour necrosis factor inadequate responders. J Crohn\u2019s Colitis 10(suppl. 1):S12\u2013S13","journal-title":"J Crohn\u2019s Colitis"},{"key":"3069_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/00042737-199710000-00004","volume":"9","author":"E Louis","year":"1997","unstructured":"Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary JY (1997) A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn\u2019s disease. Eur J Gastroenterol Hepatol 9:939\u2013944","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3069_CR29","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1007\/s10620-009-1016-9","volume":"55","author":"F Ljuca","year":"2010","unstructured":"Ljuca F, Gegic A, Salkic NN, Pavlovic-Calic N (2010) Circulating cytokines reflect mucosal inflammatory status in patients with Crohn\u2019s disease. Dig Dis Sci 55:2316\u20132326","journal-title":"Dig Dis Sci"},{"key":"3069_CR30","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/ajg.2013.354","volume":"108","author":"WA Faubion Jr","year":"2013","unstructured":"Faubion WA Jr, Fletcher JG, O\u2019Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME (2013) EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn\u2019s disease activity: role of cross-sectional imaging. Am J Gastroenterol 108:1891\u20131900","journal-title":"Am J Gastroenterol"},{"key":"3069_CR31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology 70:439\u2013444","journal-title":"Gastroenterology"},{"key":"3069_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM (1980) A simple index of Crohn\u2019s-disease activity. Lancet 1:514","journal-title":"Lancet"},{"key":"3069_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82\u201386","journal-title":"BMJ"},{"key":"3069_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625\u20131629","journal-title":"N Engl J Med"},{"key":"3069_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/gim.2017.82","volume":"20","author":"G Richter","year":"2018","unstructured":"Richter G, Krawczak M, Lieb W, Wolff L, Schreiber S, Buyx A (2018) Broad consent for health care-embedded biobanking: understanding and reasons to donate in a large patient sample. Genet Med 20:76\u201382","journal-title":"Genet Med"},{"key":"3069_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00005176-199102000-00016","volume":"12","author":"JS Hyams","year":"1991","unstructured":"Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE (1991) Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 12:233\u2013236","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3069_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/gut.32.8.913","volume":"32","author":"SH Murch","year":"1991","unstructured":"Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT (1991) Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32:913\u2013917","journal-title":"Gut"},{"key":"3069_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/08923979209005404","volume":"14","author":"M Maeda","year":"1992","unstructured":"Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, Tsuji Y, Akiyama S, Tsuji N, Niitsu Y (1992) Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 14:451\u2013461","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"3069_CR39","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/clinchem\/47.7.1297","volume":"47","author":"M Komatsu","year":"2001","unstructured":"Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N (2001) Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 47:1297\u20131301","journal-title":"Clin Chem"},{"key":"3069_CR40","first-page":"211","volume":"10","author":"N Avdagic","year":"2013","unstructured":"Avdagic N, Babic N, Seremet M, Delic-Sarac M, Drace Z, Denjalic A, Nakas-Icindic E (2013) Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. Med Glas (Zenica) 10:211\u2013216","journal-title":"Med Glas (Zenica)"},{"key":"3069_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","volume":"81","author":"TT MacDonald","year":"1990","unstructured":"MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A (1990) Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81:301\u2013305","journal-title":"Clin Exp Immunol"},{"key":"3069_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","volume":"339","author":"CP Braegger","year":"1992","unstructured":"Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89\u201391","journal-title":"Lancet"},{"key":"3069_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jcp.46.8.757","volume":"46","author":"S Nicholls","year":"1993","unstructured":"Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 46:757\u2013760","journal-title":"J Clin Pathol"},{"key":"3069_CR44","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","volume":"106","author":"EJ Breese","year":"1994","unstructured":"Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT (1994) Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106:1455\u20131466","journal-title":"Gastroenterology"},{"key":"3069_CR45","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1111\/j.1572-0241.2002.07029.x","volume":"97","author":"Y Tsukada","year":"2002","unstructured":"Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N (2002) Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 97:2820\u20132828","journal-title":"Am J Gastroenterol"},{"key":"3069_CR46","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","volume":"22","author":"U Billmeier","year":"2016","unstructured":"Billmeier U, Dieterich W, Neurath MF, Atreya R (2016) Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 22:9300\u20139313","journal-title":"World J Gastroenterol"},{"key":"3069_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00054725-199503000-00003","volume":"1","author":"J Hyams","year":"1995","unstructured":"Hyams J, Markowitz J, Treem W, Davis P, Grancher K, Daum F (1995) Characterization of hepatic abnormalities in children with inflammatory bowel disease. Inflamm Bowel Dis 1:27\u201333","journal-title":"Inflamm Bowel Dis"},{"key":"3069_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/00365520410005162","volume":"39","author":"S Vadstrup","year":"2004","unstructured":"Vadstrup S (2004) Subnormal alanine aminotransferase values in blood of patients with Crohn disease. Scand J Gastroenterol 39:554\u2013556","journal-title":"Scand J Gastroenterol"},{"key":"3069_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4137\/CGast.S13125","volume":"7","author":"M Cappello","year":"2014","unstructured":"Cappello M, Randazzo C, Bravata I, Licata A, Peralta S, Craxi A, Almasio PL (2014) Liver function test abnormalities in patients with inflammatory bowel diseases: a hospital-based survey. Clin Med Insights Gastroenterol 7:25\u201331","journal-title":"Clin Med Insights Gastroenterol"},{"key":"3069_CR50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MPG.0000000000000409","volume":"59","author":"A Goyal","year":"2014","unstructured":"Goyal A, Hyams JS, Lerer T, Leleiko NS, Otley AR, Griffiths AM, Rosh JR, Cabrera JM, Oliva-Hemker MM, Mack DR, Rick JN, Pfefferkorn MD, Carvalho R, Grossman AB, Hitch MC, Sudel B, Kappelman MD, Saeed SA, Faubion WA, Schaefer ME, Markowitz JF, Keljo DJ (2014) Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease. J Pediatr Gastroenterol Nutr 59:321\u2013323","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3069_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/MPG.0000000000000672","volume":"60","author":"AJ Pusateri","year":"2015","unstructured":"Pusateri AJ, Kim SC, Dotson JL, Balint JP, Potter CJ, Boyle BM, Crandall WV (2015) Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 60:592\u2013597","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3069_CR52","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MEG.0000000000000350","volume":"27","author":"T Schroder","year":"2015","unstructured":"Schroder T, Schmidt KJ, Olsen V, Moller S, Mackenroth T, Sina C, Lehnert H, Fellermann K, Buning J (2015) Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. Eur J Gastroenterol Hepatol 27:698\u2013704","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3069_CR53","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s10620-017-4495-0","volume":"62","author":"RM Carr","year":"2017","unstructured":"Carr RM, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A, Forde KA, Reddy KR, Lichtenstein GR (2017) Intestinal inflammation does not predict nonalcoholic fatty liver disease severity in inflammatory bowel disease patients. Dig Dis Sci 62:1354\u20131361","journal-title":"Dig Dis Sci"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-018-3069-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-018-3069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-018-3069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T21:21:59Z","timestamp":1604265719000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-018-3069-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s00384-018-3069-8","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"29 April 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GHW and DS are employed by CONARIS Research Institute AG, which has out-licenced its interleukin-6 inhibitor olamkicept to Ferring Pharmaceuticals. UL, BBR and TMR are employed by Ferring Pharmaceuticals. SSc heads the supervisory board of CONARIS. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was granted by the ethics committee of the medical faculty of Kiel University prior to the study (AZ D489\/14). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. The ethical concept of healthcare-embedded biobanking with broad informed consents as implemented in Kiel has recently been described [].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}